Last September, TrialSite interviewed the president of the Rescue Group, the largest healthcare group in the Caribbean nation of the Dominican Republic. At that time, TrialSite’s founder…
Researchers led by the Ministry of Public Health Tucumán, Argentina, recently completed the IVER-Leve clinical trial, organized in response to the challenges with the COVID-19…
Growing demands for the use of ivermectin in the Philippines as a low cost treatment for COVID-19 continues to drive a wedge in society between…
On January 14, the NIH updated it’s COVID-19 Treatment Guidelines on Ivermectin. The recommendation against its use except in clinical trials was lifted. However, the language of…
Recently, two studies were published which led many to question whether masks are protective against COVID-19 and if they are even necessary. Let’s answer these…
A massive study in the United Kingdom hasn’t received much press attention across the Pond in America but perhaps should so. Perhaps the outcomes of…
Morimasa Yagisawa, visiting professor at Kitasato University, Omura Satoshi Memorial Institute in Tokyo, went on the record that the World Health Organization, drug regulators, and…
Yet another clinical trial result points out the possible benefits of ivermectin in relations to COVID-19 treatments. This time, a study led by researchers from Afyonkarahisar…
First known as REGN-COV2 and now as Casirivimab and Imdevimab, Regeneron’s monoclonal antibody cocktail authorized by the U.S. Food and Drug Administration (FDA) on an…
A nonsteroidal antiandrogen (NSAA), classified as a selective, high-affinity silent antagonist of the androgen receptor (AR), currently under development by a Chinese biotech company was…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
